TERN vs. INZY, VRCA, CRMD, AKBA, ERAS, AVIR, CTNM, XOMA, RAPT, and AQST
Should you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Inozyme Pharma (INZY), Verrica Pharmaceuticals (VRCA), CorMedix (CRMD), Akebia Therapeutics (AKBA), Erasca (ERAS), Atea Pharmaceuticals (AVIR), Contineum Therapeutics (CTNM), XOMA (XOMA), RAPT Therapeutics (RAPT), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical preparations" industry.
Terns Pharmaceuticals (NASDAQ:TERN) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
Terns Pharmaceuticals received 1 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 80.49% of users gave Inozyme Pharma an outperform vote while only 59.65% of users gave Terns Pharmaceuticals an outperform vote.
Terns Pharmaceuticals' return on equity of -33.55% beat Inozyme Pharma's return on equity.
Terns Pharmaceuticals currently has a consensus price target of $14.94, indicating a potential upside of 218.50%. Inozyme Pharma has a consensus price target of $17.00, indicating a potential upside of 279.46%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than Terns Pharmaceuticals.
In the previous week, Terns Pharmaceuticals had 2 more articles in the media than Inozyme Pharma. MarketBeat recorded 2 mentions for Terns Pharmaceuticals and 0 mentions for Inozyme Pharma. Terns Pharmaceuticals' average media sentiment score of 1.02 beat Inozyme Pharma's score of 0.00 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.
Terns Pharmaceuticals has a beta of -0.63, meaning that its stock price is 163% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.
98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 17.4% of Terns Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of Inozyme Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Inozyme Pharma has lower revenue, but higher earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Terns Pharmaceuticals beats Inozyme Pharma on 10 of the 16 factors compared between the two stocks.
Get Terns Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Terns Pharmaceuticals Competitors List
Related Companies and Tools
